Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine
Alcindo Busanello1, Caroline Queiroz Leal2, Luis Ricardo Peroza3
1Programa de Pós-Graduação em Farmacologia, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
Abstract:
Typical antipsychotics, which are commonly used to treat schizophrenia, cause motor disorders such as tardive dyskinesia (TD) in humans and orofacial dyskinesia (OD) in rodents. The disease mechanisms as well as treatment effectiveness are still unknown. In this study, we investigated the effect of resveratrol, a polyphenol with neuroprotective properties, on behavioral changes induced by chronic treatment with fluphenazine in rats and the possible relationship between monoamine oxidase (MAO) activity and vacuous chewing movements (VCMs). Rats were treated for 18 weeks with fluphenazine enantate [25 mg/kg, intramuscularly (i.m.), every 21 days] and/or resveratrol (20 mg/kg, offered daily in drinking water). Next, body weight gain, behavioral parameters (VCMs and open field tests-locomotor and rearing activity), and MAO activity were evaluated. Fluphenazine treatment reduced body weight gain, number of crossings and rearings, and the co-treatment with resveratrol did not affect these alterations. Fluphenazine increased the prevalence and intensity of VCMs and the co-treatment with resveratrol reduced the VCMs. Furthermore, a negative correlation was found between the number of VCMs and MAO-B activity in the striatum of rats. Our data suggest that resveratrol could be promissory to decrease OD. Moreover, MAO-B activity in the striatum seems to be related to VCMs intensity.
Insights
Resveratrol may reduce orofacial dyskinesia (OD) in rats, a motor disorder linked to antipsychotic use. This study found resveratrol decreased vacuous chewing movements (VCMs) and suggests a link between MAO-B activity and OD intensity.
Area of Science:
- Neuroscience
- Pharmacology
- Behavioral Science
Background:
- Typical antipsychotics, used for schizophrenia, can induce motor disorders like tardive dyskinesia (TD) in humans and orofacial dyskinesia (OD) in rodents.
- The underlying mechanisms and effective treatments for these drug-induced motor disorders remain unclear.
Purpose of the Study:
- To investigate the neuroprotective effects of resveratrol on fluphenazine-induced behavioral changes in rats.
- To explore the potential relationship between monoamine oxidase (MAO) activity and vacuous chewing movements (VCMs), an animal model of OD.
Main Methods:
- Rats received chronic intramuscular fluphenazine enantate and/or daily resveratrol treatment for 18 weeks.
- Evaluated body weight gain, locomotor and rearing activity (open field tests), and vacuous chewing movements (VCMs).
- Assessed monoamine oxidase (MAO) activity in rat striatum.
Main Results:
- Fluphenazine treatment reduced body weight gain and locomotor activity, effects not altered by resveratrol co-treatment.
- Fluphenazine significantly increased the prevalence and intensity of VCMs.
- Resveratrol co-treatment notably reduced VCMs.
- A negative correlation was observed between VCM intensity and striatal MAO-B activity.
Conclusions:
- Resveratrol shows promise as a potential therapeutic agent to mitigate orofacial dyskinesia (OD).
- Monoamine oxidase-B (MAO-B) activity in the striatum appears to be associated with the intensity of VCMs, suggesting a role in OD pathogenesis.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:22Alzheimer's Disease: Treatment